NEWSSHIFTBIO is delighted to share the preprint of our lead program, SIRP-NNP

31 May 2024

We are delighted to share the preprint of our lead program, SIRP-NNP.

This manuscript showcases the exceptional therapeutic efficacy of SIRP-NNP in treating acute liver failure, along with our rigorous manufacturing process. SIRP-NNP demonstrates a dual-mode action therapeutic approach to this rare disease, which currently lacks effective treatment options.
The study further highlights our comprehensive NNP manufacturing process, from engineering primary cells to purifying NNPs, ensuring large-scale scalability, high yield, and high purity.

This work was led by the outstanding members of SHIFTBIO INC., in collaboration with RoosterBio.

Check out the full preprint here:
https://www.biorxiv.org/content/10.1101/2024.05.24.592430v1